Korea Investment CORP Has $5.90 Million Holdings in United Therapeutics Corporation $UTHR

Key Points

• Korea Investment CORP cut its stake in United Therapeutics by 54.7% in Q3, selling 17,005 shares and finishing the quarter with 14,084 shares worth about $5.90 million.
• Several large institutions piled into UTHR—Norges Bank initiated a ~$136.5 million stake and Invesco, AQR and Balyasny materially increased positions—leaving institutional investors owning 94.08% of the stock.
• Corporate insiders have been net sellers: COO Michael Benkowitz sold 22,500 shares on Dec. 15 for about $11.17 million, and insiders sold 338,947 shares (~$165.5 million) over the past 90 days while still owning 10.30% of the company.

Korea Investment CORP trimmed its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 54.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,084 shares of the biotechnology company's stock after selling 17,005 shares during the quarter. Korea Investment CORP's holdings in United Therapeutics were worth $5,904,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of United Therapeutics during the 2nd quarter worth about $136,453,000. Invesco Ltd. raised its stake in shares of United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company's stock valued at $254,219,000 after acquiring an additional 419,588 shares in the last quarter. AQR Capital Management LLC lifted its holdings in United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company's stock worth $362,876,000 after purchasing an additional 364,713 shares during the last quarter. Balyasny Asset Management L.P. lifted its holdings in United Therapeutics by 863.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company's stock worth $43,886,000 after purchasing an additional 136,883 shares during the last quarter. Finally, Sofinnova Investments Inc. bought a new position in shares of United Therapeutics in the second quarter valued at approximately $34,055,000. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the firm's stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $496.30, for a total value of $11,166,750.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders sold 338,947 shares of company stock valued at $165,516,573. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $532.82 on Friday. The firm has a market capitalization of $23.35 billion, a price-to-earnings ratio of 19.10, a P/E/G ratio of 1.96 and a beta of 0.84. The company's fifty day moving average is $485.89 and its two-hundred day moving average is $458.53. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $548.12.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same quarter in the prior year, the business earned $6.19 earnings per share. The firm's revenue for the quarter was up 7.4% on a year-over-year basis. As a group, sell-side analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on UTHR. Weiss Ratings reaffirmed a "buy (b)" rating on shares of United Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada lifted their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an "outperform" rating in a report on Thursday, February 26th. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 26th. UBS Group raised their price target on United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a research report on Thursday, March 5th. Finally, Oppenheimer boosted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $548.09.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.